Rhythm Pharmaceuticals Inc
$ 99.25
-6.14%
31 Jul - close price
- Market Cap 6,807,912,000 USD
- Current Price $ 99.25
- High / Low $ 106.87 / 98.44
- Stock P/E N/A
- Book Value 1.80
- EPS -3.13
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -1.01 %
- 52 Week High 122.20
- 52 Week Low 74.50
About
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$138.80
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-26 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-26 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-01 |
| Reported EPS | -0.83 | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 | -0.73 | -0.55 | -2.35 | -0.7 | -0.76 | -0.82 |
| Estimated EPS | -0.86 | -0.79 | -0.73 | -0.67 | -0.68 | -0.73 | -0.87 | -0.72 | -2.39 | -0.7 | -0.76 | -0.78 |
| Surprise | 0.03 | 0.06 | -0.09 | -0.08 | -0.13 | 0.01 | 0.14 | 0.17 | 0.04 | 0 | 0 | -0.04 |
| Surprise Percentage | 3.4884% | 7.5949% | -12.3288% | -11.9403% | -19.1176% | 1.3699% | 16.092% | 23.6111% | 1.6736% | 0% | 0% | -5.1282% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.81 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RYTM
2026-08-02 11:10:44
Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is showing divergent sentiment across horizons, indicating choppy conditions. AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each with specific entry, target, and stop loss levels. The analysis highlights an exceptional 48.4:1 risk-reward setup, targeting a 14.2% gain against a 0.3% risk.
2026-08-01 06:09:50
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) generated a total revenue of $194.77 million USD last year. The majority of this revenue, $189.76 million USD, came from its Therapeutics segment. The United States was the largest geographical contributor, accounting for $133.55 million USD of the revenue.
2026-07-31 11:10:54
This article provides a technical analysis of Rhythm Pharmaceuticals Inc (RYTM), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It shows that RYTM's stock price is currently trading between resistance at $114.09 and support at $99.21, suggesting suitability for range-bound swing trading. The analysis includes a summary of indicator signals (Sell, Neutral, Buy) and moving average data, concluding with a neutral overall signal based on technical analysis.
2026-07-31 09:10:54
Rhythm Pharmaceuticals Inc (RYTM) has strong fundamentals, high growth potential, and is considered fairly valued within the pharmaceuticals industry. Institutional ownership is high, and analysts largely rate it as a "Buy" with an expected upward trend in the medium term. The company specializes in developing precision medicines for rare MC4R pathway diseases, with its lead asset IMCIVREE already FDA-approved.
2026-07-28 13:41:19
Rhythm Pharmaceuticals, Inc. (RYTM) is predicted to surpass Q2 earnings estimates, despite an expected year-over-year decline in earnings but higher revenues. The company's Zacks Earnings ESP of +1.46% combined with a Zacks Rank #3 suggests a strong probability of an earnings beat. Investors will be watching the earnings report due August 4th to see how these results impact the stock price.
2026-07-28 05:41:19
This article provides a valuation analysis of Rhythm Pharmaceuticals Inc (RYTM), highlighting its current valuation score of 9.55, which ranks 16th in the Pharmaceuticals industry. The P/E ratio is noted as -33.84, with other key metrics like P/B, P/S, and P/CF not yet disclosed by the company. The stock's current market price, market cap, and daily performance are also mentioned.
